التفاصيل البيبلوغرافية
| العنوان: |
Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. |
| المؤلفون: |
Statland, Jeffrey M., Moore, Dan, Wang, Yunxia, Walsh, Maureen, Mozaffar, Tahseen, Elman, Lauren, Nations, Sharon P., Mitsumoto, Hiroshi, Fernandes, J. Americo, Saperstein, David, Hayat, Ghazala, Herbelin, Laura, Karam, Chafic, Katz, Jonathan, Wilkins, Heather M., Agbas, Abdulbaki, Swerdlow, Russell H., Santella, Regina M., Dimachkie, Mazen M., Barohn, Richard J. |
| المصدر: |
Muscle & Nerve; Feb2019, Vol. 59 Issue 2, p201-207, 7p |
| مصطلحات موضوعية: |
AMYOTROPHIC lateral sclerosis, COMPARATIVE studies, HYDROCARBONS, RESEARCH methodology, MEDICAL cooperation, HEALTH outcome assessment, QUALITY of life, RESEARCH, RESEARCH funding, DNA-binding proteins, EVALUATION research, RANDOMIZED controlled trials, TREATMENT effectiveness, NEUROPROTECTIVE agents, BLIND experiment, RETROSPECTIVE studies, SEVERITY of illness index |
| مصطلحات جغرافية: |
UNITED States |
| مستخلص: |
Introduction: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS).Methods: We performed a randomized, double-blind, placebo-controlled trial of 80 ALS participants with enrichment of the placebo group with historical controls (n = 177) at 10 centers in the United States. Participants were randomized in a 3:1 ratio to 2 mg/day rasagiline or placebo. The primary outcome was average slope of decline on the ALS Functional Rating Scale-Revised (ALSFRS-R). Secondary measures included slow vital capacity, survival, mitochondrial and molecular biomarkers, and adverse-event reporting.Results: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical control cohorts. Rasagiline did not show signs of drug-target engagement in urine and blood biomarkers. Rasagiline was well tolerated with no serious adverse events.Discussion: Rasagiline did not alter disease progression compared with controls over 12 months of treatment. Muscle Nerve 59:201-207, 2019. [ABSTRACT FROM AUTHOR] |
|
Copyright of Muscle & Nerve is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
